<DOC>
	<DOCNO>NCT00470197</DOCNO>
	<brief_summary>Drugs use chemotherapy , flavopiridol , cytarabine , mitoxantrone , work different way stop growth cancer cell , either kill cell stop divide . Giving new schedule one drug ( combination chemotherapy ) may kill cancer cell . This phase I trial study side effect , best dose , best schedule flavopiridol give together cytarabine mitoxantrone treat patient relapsed refractory acute leukemia .</brief_summary>
	<brief_title>Flavopiridol , Cytarabine , Mitoxantrone Treating Patients With Relapsed Refractory Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicities escalate dos flavopiridol administer `` hybrid '' bolus-infusion schedule give time sequence cytarabine mitoxantrone hydrochloride patient refractory relapse acute leukemia . II . Determine incidence clinical response patient treat regimen . OUTLINE : This dose-escalation study flavopiridol . Patients receive flavopiridol IV 30 minute day 1 , 2 , 3 . Patients receive cytarabine IV continuously 72 hour begin day 6 mitoxantrone hydrochloride IV 60-120 minute day 9 . Treatment repeat every 35-63 day 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3 2 6 patient experience dose-limiting toxicity . Serum bone marrow sample collect baseline , , completion treatment future study . Flavopiridol level measure baseline day 1-3 pharmacokinetics .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Pathologically confirm acute myeloid leukemia acute lymphoblastic leukemia : Relapsed &gt; = 1 time OR refractory disease : Patients fail primary induction therapy relapse achieve complete remission eligible receive = &lt; 3 prior course induction/reinduction therapy Relapsed &gt; = 1 time OR refractory disease Patients fail primary induction therapy relapse achieve complete remission eligible receive = &lt; 3 prior course induction/reinduction therapy No active CNS leukemia ECOG performance status 02 AST ALT = &lt; 5 time upper limit normal ( ULN ) Alkaline phosphatase = &lt; 5 time ULN Bilirubin = &lt; 2.0 mg/dL Creatinine = &lt; 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception LVEF &gt; = 45 % MUGA ECHO No active , uncontrolled infection No lifethreatening illness No mental deficit and/or psychiatric history would preclude study compliance No active graftvshost disease Recovered prior therapy At least 24 hour since prior hydroxyurea , steroid , imatinib mesylate , arsenic trioxide , interferon , leukapheresis blast count control At least 4 week since prior stem cell transplantation ( autologous allogeneic ) At least 4 day since prior growth factor At least 3 week since prior chemotherapy , except nonaplasia produce treatment ( e.g. , lowdose cyclophosphamide , hydroxyurea , interferon , imatinib mesylate , mercaptopurine , thalidomide , azacitidine , decitabine ) No prior flavopiridol No concurrent chemotherapy , radiotherapy , immunotherapy No acute promyelocytic leukemia ( M3 ) No hyperleukocytosis &gt; 50,000 blasts/mm^3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>